Boehringer Ingelheim Vetmedica Gmbh

Other

Akzo Nobel N.v.

Dermal Research Laboratories, Inc.

Bayer Corporation

Akzo Nobel

Baker Aktiengesellschaft

Boehringer Ingelheim Animal Health USA Inc.

Kristina J Hennessy

Karen K Brown

Phillip Wayne Hayes

Ronald C Montelaro

Bridget Puffer

Charles Issel

Jennifer K Lane

Harold G Brown

Carol A Cooper

Feng Li

Sandra L Trump

Norbert Schmeer

Jodi Craigo

Rebecca A Atherton

Laurent Viel

Andres Diaz-Mendez

Jean A Hallstrom

Philip W Hayes

Andrés Diaz-Mendez

The disclosure provides for immunogenic compositions against Pigeon Fever, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include otherpathogens.

Immunogenic compositions and methods for pigeon fever

The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.

West Nile Virus vaccine

The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates with or without natural or synthetic essential oils can work effectively as a topical, oral or mucosal pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers and prevent and treat numerous other conditions and diseases. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion, metastatic and coronary cascades.

Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same

The disclosure provides for immunogenic compositions against Equine Rhinitis Virus, particularly Equine Rhinitis A and B Virus, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.

Equine rhinitis vaccine

A process for making an adjuvanted vaccine comprising host albumin. The process comprises mixing host serum or host serum with an antigen, and then mixing the resulting mixture with an adjuvant.

Process for making an adjuvanted vaccine comprising host albumin

The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.

EIA vaccine and diagnostic

Disclosed herein is a serum-based adjuvanted vaccine which is substantially free of non-host albumin and the use thereof in reducing or preventing post-vaccination systemic reactions.

Adjuvanted vaccine which is substantially free of non-host albumin

Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Preferably said composition encompasses at least one deletion in a lentivirus which provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease without converting to a seropositive status on the Coggin's Test or any other test which measures p26.

EIAV p26 deletion vaccine and diagnostic

The present invention relates to feline vaccines comprising inactivated a non reactive Chlamydia psittaci for prevention and treatment of chlamydia diseases in cats.

Feline vaccines containing Chlamydia psittaci and method for making the

Growing community of inventors

Leawood, KS, United States of America

Kristina J Hennessy